Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuvalent, Inc. (NUVL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nuvalent is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detailed information on clinical progress, financing activities, and key business agreements related to its targeted oncology pipeline.
Recent Form 8-K filings describe pivotal and preliminary data for neladalkib in ALK-positive NSCLC from the ALKOVE-1 Phase 1/2 trial, pivotal data for zidesamtinib in ROS1-positive NSCLC from the ARROS-1 Phase 1/2 trial, and the initiation of the ALKAZAR Phase 3 trial in TKI-naïve ALK-positive NSCLC. Other 8-Ks outline the completion and FDA acceptance of a New Drug Application for zidesamtinib in TKI pre-treated ROS1-positive NSCLC, plans for an NDA submission for neladalkib, and the assignment of a PDUFA target action date for zidesamtinib.
Filings also document Nuvalent’s capital markets activity, including an underwriting agreement for a public offering of Class A common stock under an automatically effective shelf registration statement on Form S-3, and the company’s estimate that proceeds from the offering, together with existing cash, cash equivalents, and marketable securities, would fund operations into 2029. Additional disclosures cover a preexisting royalty interest on future net sales of neladalkib and zidesamtinib, as well as periodic 8-Ks furnishing quarterly financial results press releases.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight the main points of each document, helping readers quickly understand clinical data updates, NDA milestones, financing terms, and other material events. Users can review 10-K and 10-Q reports, 8-K current reports, registration statements, and exhibits, and use the AI-generated insights to navigate lengthy technical and legal language more efficiently while researching NUVL.
Nuvalent Director Matthew Shair reported multiple securities transactions on June 18, 2025. The transactions include:
- Acquisition of 2,647 restricted stock units (RSUs) at $0.00, convertible to Class A Common Stock. These RSUs vest fully by June 18, 2026 or the next annual stockholder meeting
- Grant of stock options to purchase 4,147 shares at $75.53 per share, expiring June 18, 2035
Following these transactions, Shair directly owns 1,429,844 shares of Class A Common Stock and indirectly controls 216,522 shares through the Matthew D. Shair 2021 Irrevocable Family Trust. The compensation package appears to be part of standard director remuneration, with both RSUs and options subject to one-year vesting periods tied to continued service.
Nuvalent director Anna Protopapas received new equity compensation grants on June 18, 2025, consisting of:
- 2,647 Restricted Stock Units (RSUs) of Class A Common Stock at $0.00, which vest in full on the earlier of June 18, 2026, or the next annual stockholder meeting
- 4,147 Stock Options with a strike price of $75.53, exercisable until June 18, 2035, following the same vesting schedule as the RSUs
Following these transactions, Protopapas directly owns 5,146 shares of Class A Common Stock and 4,147 stock options. These grants appear to be part of the company's director compensation program, with a one-year vesting period tied to continued service on the board.
Joseph Pearlberg, Director at Nuvalent (NUVL), reported two significant equity transactions on June 18, 2025:
- Acquired 2,647 Restricted Stock Units (RSUs) at $0.00, convertible to Class A Common Stock. These RSUs will fully vest on June 18, 2026, or at the next annual stockholder meeting, bringing total direct ownership to 5,146 shares
- Received stock options to purchase 4,147 shares at an exercise price of $75.53, expiring June 18, 2035. Options follow the same vesting schedule as the RSUs
Important disclosure: Pearlberg, an employee of Deerfield Management Company, holds these securities for Deerfield's benefit and direction, disclaiming personal beneficial ownership. This suggests an institutional relationship between Deerfield Management and Nuvalent's governance structure.
Nuvalent, Inc. (NUVL) filed a Form 4 disclosing routine director equity compensation. Director Michael L. Meyers reported transactions dated 18 June 2025.
- Restricted Stock Units (RSUs): 2,647 Class A shares awarded at no cost. RSUs vest in full on the earlier of 18 June 2026 or the company’s next annual shareholders’ meeting, contingent on continued service.
- Stock Options: 4,147 options granted with a US$75.53 exercise price and 18 June 2035 expiry. The entire option grant vests on the same schedule as the RSUs.
- Post-transaction ownership: Meyers now directly holds 5,146 Class A shares. All newly reported securities were granted, not purchased on the open market.
The filing reflects standard annual board compensation rather than an open-market purchase or sale. As such, the event is generally viewed as neutral to Nuvalent’s valuation, though the additional insider ownership modestly aligns director and shareholder interests.
Nuvalent, Inc. (NASDAQ: NUVL) – Form 4 filing dated 20 Jun 2025
Director Grant C. Bogle reported the receipt of two equity awards on 18 Jun 2025:
- 2,647 restricted stock units (RSUs) representing Class A common shares. The RSUs were awarded at no cash cost and will vest in full on the earlier of 18 Jun 2026 or the company’s next annual meeting, conditional on continued board service.
- 4,147 stock options with an exercise price of $75.53, also vesting on the same schedule and expiring on 18 Jun 2035.
Following the grant, Bogle’s direct beneficial ownership stands at 5,847 Class A shares and 4,147 vested/unvested options. The transaction was coded “A” (award) and involved no open-market purchase or sale of shares, indicating routine, board-approved compensation rather than an insider-driven valuation signal.
The share amounts involved are modest relative to Nuvalent’s public float; therefore, any dilution effect is immaterial. No changes to corporate strategy, earnings outlook, or insider sentiment beyond standard compensation practices are implied by this filing.
Nuvalent, Inc. (NUVL) filed a Form 4 disclosing that director Christy J. Oliger received new equity awards on 18 June 2025.
- 3,971 Restricted Stock Units (RSUs): Granted at no cost. The RSUs convert to an equal number of Class A shares in three equal annual installments beginning one year from the grant date, provided the director remains in service.
- 6,119 Stock Options: Right to buy Class A shares at an exercise price of $75.53, expiring 18 June 2035. Vesting occurs monthly over the three-year period following the grant.
Post-grant, Oliger directly owns 3,971 Class A shares and holds derivative rights (options) to acquire an additional 6,119 shares. The filing reports no sales or dispositions.
These awards form part of Nuvalent’s standard director compensation package, creating long-term alignment with shareholder interests through multi-year vesting schedules. Because the transactions are grants rather than market purchases or sales, they do not immediately affect cash flow or trading volume but do incrementally increase potential dilution if options are exercised in the future.
Form 3 Overview: Nuvalent, Inc. (NUVL) filed an Initial Statement of Beneficial Ownership for Ms. Christy J. Oliger on 06/20/2025, reporting an event date of 06/18/2025.
Key Details:
- Reporting Person: Christy J. Oliger
- Relationship to Issuer: Director (no other roles indicated)
- Beneficial Ownership: The filer explicitly states “No securities are beneficially owned.”
- Filing Type: Form filed by one reporting person; accompanied by a Power of Attorney (Exhibit 24) signed by attorney-in-fact Nathan N. McConarty.
Investor Takeaway: A Form 3 signals an insider’s entry into the company’s reporting framework. However, because the form shows zero shares owned, there is no immediate dilution, concentration change, or valuation signal. The filing is largely administrative, confirming Ms. Oliger’s board position and future reporting obligations under Section 16(a).
Nuvalent, Inc. (NASDAQ: NUVL) filed a Form 8-K covering two corporate-governance items dated June 18, 2025.
Board change (Item 5.02): The Board unanimously elected Christy J. Oliger as an independent Class III director, effective immediately. She will serve until the 2027 annual meeting and join the Audit Committee. Compensation aligns with the existing non-employee director policy and includes:
- Initial stock option for 6,119 shares at an exercise price of $75.53, vesting monthly over three years.
- Initial RSU award of 3,971 shares, vesting annually over three years.
- Annual cash retainers and ongoing equity grants as stipulated in the policy.
2025 Annual Meeting results (Item 5.07): Quorum was strong with 64.38 million votes representing 97.01 % of outstanding shares. Outcomes were:
- Director elections: Grant Bogle (99.87 % support); James R. Porter, Ph.D. (99.78 %); Anna Protopapas (86.27 %).
- Say-on-pay: Approved with 83.8 % (53.52 m for, 10.36 m against).
- Auditor ratification: KPMG LLP re-approved with 99.98 % support.
Investor take-away: The filing is largely procedural. The addition of an experienced independent director strengthens oversight, while voting results confirm broad shareholder support for existing leadership and compensation structure.
FAQ
What is the current stock price of Nuvalent (NUVL)?
What is the market cap of Nuvalent (NUVL)?
